Pos­i­tive piv­otal Lil­ly da­ta set stage for Taltz ap­proval in non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis

Hav­ing se­cured ap­proval for pso­ri­at­ic arthri­tis and plaque pso­ri­a­sis, Lil­ly is plot­ting to get its mon­o­clon­al an­ti­body Taltz across the fin­ish line for a form of in­flam­ma­to­ry arthri­tis in which there is no vis­i­ble ev­i­dence of dam­age on X-rays — non-ra­di­ograph­ic ax­i­al spondy­loarthri­tis (nr-AxS­pA). On Mon­day, the drug­mak­er re­port­ed the treat­ment had cleared a late-stage study, set­ting the stage for a reg­u­la­to­ry sub­mis­sion lat­er this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER